Progress for resectable pancreatic [corrected] cancer?: a population-based assessment of US practices.
about
Postoperative mortality following multi-modality therapy for pancreatic cancer: Analysis of the SEER-Medicare data.Trajectory of care and use of multimodality therapy in older patients with pancreatic adenocarcinoma.Underutilization of therapy for hepatocellular carcinoma in the medicare population.Impact of adjuvant radiotherapy on survival after pancreatic cancer resection: an appraisal of data from the national cancer data base.Pulmonary metastases in pancreatic cancer, is there a survival influence?Minimally Invasive Pancreaticoduodenectomy Does Not Improve Use or Time to Initiation of Adjuvant Chemotherapy for Patients With Pancreatic Adenocarcinoma.Neoadjuvant treatment for resectable pancreatic adenocarcinoma.CT Imaging Biomarkers Predict Clinical Outcomes After Pancreatic Cancer Surgery.Management of patients with pancreatic adenocarcinoma: national trends in patient selection, operative management, and use of adjuvant therapy.Trends in Receipt and Timing of Multimodality Therapy in Early-Stage Pancreatic Cancer.Costs and trends in pancreatic cancer treatmentTime trends in the treatment and prognosis of resectable pancreatic cancer in a large tertiary referral centre.Early Recurrence and Omission of Adjuvant Therapy after Pancreaticoduodenectomy Argue against a Surgery-First Approach.Neoadjuvant therapy is associated with a reduced lymph node ratio in patients with potentially resectable pancreatic cancer.Influence of patient, physician, and hospital factors on 30-day readmission following pancreatoduodenectomy in the United States.Surgical therapy for early hepatocellular carcinoma in the modern era: a 10-year SEER-medicare analysis.Outcomes after robot-assisted pancreaticoduodenectomy for periampullary lesions.Outcomes following resection of pancreatic cancer.Outcomes in operative management of pancreatic cancer.Improved long-term outcomes after resection of pancreatic adenocarcinoma: a comparison between two time periods.Type of Resection (Whipple vs. Distal) Does Not Affect the National Failure to Provide Post-resection Adjuvant Chemotherapy in Localized Pancreatic Cancer.Prognosis of small bowel adenocarcinoma in Crohn's disease compares favourably with de novo small bowel adenocarcinoma.A comparative analysis of survival outcomes between pancreatectomy and chemotherapy for elderly patients with adenocarcinoma of the pancreas.Impact of early disease progression and surgical complications on adjuvant chemotherapy completion rates and survival in patients undergoing the surgery first approach for resectable pancreatic ductal adenocarcinoma - A population-based cohort studyUptake and patterns of use of gemcitabine for metastatic pancreatic cancer: a population-based study.Is it worth looking? Abdominal imaging after pancreatic cancer resection: a national study.Borderline Resectable Pancreatic Cancer.Treatment sequencing for resectable pancreatic cancer: influence of early metastases and surgical complications on multimodality therapy completion and survival.Survival after Resection of Pancreatic Adenocarcinoma: Results from a Single Institution over Three Decades
P2860
Q31157700-DA6DAAC5-1BCD-429B-B6CD-42823C61699CQ33905392-D64BC9BC-FB5E-43A8-9184-F3B03C5D8E1BQ34143512-D0854922-F459-4713-AB84-8A91E39F68C9Q34774546-15C7D73C-6B56-491C-9C3E-A0E372CCFC02Q35419454-77E97222-C656-41F7-A8B2-03AC61E0A415Q35834208-855F535B-3203-44EB-AEE8-8233DE47C6EEQ36526141-D06A705D-3659-466F-970D-C57E43318AEFQ36566939-B041A7EE-F94C-4087-8968-78C839D66E42Q36626617-0199A344-386A-44F2-BDD4-99C86560C106Q36757638-D7D8F5D5-ECD4-4B82-ACEF-4DF87755DFCEQ37246292-5797EC28-F758-4062-B4C4-658FC5B0357DQ37350310-BCA4133F-C3D1-4A82-AF5F-33E751E1ADA9Q37412058-CEC2046B-66D9-47DE-90E4-BADC66634153Q37460276-24910448-C079-430C-803B-34E8B417D586Q37698496-DD23B3EF-9AD1-4757-95BD-79ABE949C4F5Q37715129-2AB90320-643A-4BF4-BF4D-3F65D1B2BD49Q37938812-B172D1D7-0278-44C2-941F-766C7F531011Q38044710-9AC6470C-AF84-4F7D-998F-D1EE515D4329Q38238896-87122A92-F575-4E84-A384-89F7F75FB044Q38263106-CAC7F4BA-CF45-4DB4-949E-54210FF7C121Q39030076-01E2EF3E-1018-4D46-8B0E-C79F5511E302Q39360942-AD45F35B-77C2-48CF-A559-F175F725669CQ39599196-60243B8B-AF5C-4BCA-85E4-F0DC23192748Q41545288-4244402D-710E-4893-A9AA-312F2921FED4Q46053394-8FE0FB98-1FBB-4406-AF38-3D103DDC4A75Q46429238-13E8F092-67C8-4FD8-AA38-928559E27689Q46839715-40D0337A-AF13-4213-A10C-54DCF927E185Q51772050-A126D882-2AEA-4E5B-B437-E3A801172E45Q57823419-D9509AF9-848E-479F-A96F-59B2A51BF197
P2860
Progress for resectable pancreatic [corrected] cancer?: a population-based assessment of US practices.
description
2010 nî lūn-bûn
@nan
2010 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
name
Progress for resectable pancre ...... ed assessment of US practices.
@ast
Progress for resectable pancre ...... ed assessment of US practices.
@en
Progress for resectable pancre ...... ed assessment of US practices.
@nl
type
label
Progress for resectable pancre ...... ed assessment of US practices.
@ast
Progress for resectable pancre ...... ed assessment of US practices.
@en
Progress for resectable pancre ...... ed assessment of US practices.
@nl
prefLabel
Progress for resectable pancre ...... ed assessment of US practices.
@ast
Progress for resectable pancre ...... ed assessment of US practices.
@en
Progress for resectable pancre ...... ed assessment of US practices.
@nl
P2093
P356
P1433
P1476
Progress for resectable pancre ...... ed assessment of US practices.
@en
P2093
Craig C Earle
Jennifer F Tseng
Jessica P Simons
Sing Chau Ng
Theodore P McDade
Zheng Zhou
P2860
P304
P356
10.1002/CNCR.24918
P407
P577
2010-04-01T00:00:00Z